Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 35%
Buy 45%
Hold 16%
Sell 3%
Strong Sell 0%

Bulls say

Abbott Laboratories has demonstrated robust growth across multiple divisions, with the Medical Device segment achieving a 14% year-over-year increase in sales, reflecting strong demand for its innovative products, including catheters and cardiac mapping devices. The company anticipates organic sales growth of 7.5-8.5% for 2025, indicating stability and resilience in its revenue stream, even when excluding COVID-19 testing-related sales. Additionally, Abbott's commitment to returning value to shareholders is evident through its nearly 50 consecutive years of dividend increases, with a sustainable payout ratio of 46% and a yield of 1.8%.

Bears say

Abbott Laboratories is facing significant headwinds due to declining COVID-19 testing sales, which fell sharply from $8.4 billion in 2022 to $1.6 billion in 2023, impacting overall revenue performance. The company is also contending with greater macroeconomic pressures, including inflation and foreign exchange fluctuations, which are expected to challenge financial outcomes in both the first quarter and full-year 2025. Additionally, anticipated limitations to international expansion due to geopolitical factors and increased investments will likely constrain earnings power, further contributing to a negative outlook for the stock.

Abbott Labs (ABT) has been analyzed by 31 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 31 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.03, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.03, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.